UBS Group
INAB icon

UBS Group’s IN8bio INAB Stock Holding History

UBS Group’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$710 Sell
480
-297
-38% -$574 ﹤0.01% 9776
2025
Q4 		$1.82K Buy
777
+762
+5,080% +$1.45K ﹤0.01% 9462
2025
Q3 		$32 Sell
15
-464
-97% -$1.02K ﹤0.01% 10069
2025
Q2 		$1K Buy
479
+68
+17% +$276 ﹤0.01% 9692
2025
Q1 		$2.05K Sell
411
-1,551
-79% -$12.4K ﹤0.01% 9408
2024
Q4 		$15.1K Buy
1,962
+1,086
+124% +$9.54K ﹤0.01% 8056
2024
Q3 		$7.09K Buy
+876
New +$15.9K ﹤0.01% 7938
2024
Q1 		– Sell
-150
Closed -$6.22K – 9651
2023
Q4 		$6.22K Sell
150
-16
-10% -$512 ﹤0.01% 7720
2023
Q3 		$5.17K Buy
+166
New +$6.23K ﹤0.01% 7389
2023
Q2 		– Sell
-104
Closed -$4.07K – 9236
2023
Q1 		$4.07K Sell
104
-11
-10% -$614 ﹤0.01% 8239
2022
Q4 		$7.99K Sell
115
-176
-60% -$9.85K ﹤0.01% 8832
2022
Q3 		$18K Buy
291
+157
+117% +$10.5K ﹤0.01% 7523
2022
Q2 		$9K Buy
134
+6
+5% +$507 ﹤0.01% 8139
2022
Q1 		$13K Buy
128
+70
+121% +$7.83K ﹤0.01% 8054
2021
Q4 		$8K Sell
58
-57
-50% -$11.3K ﹤0.01% 9037
2021
Q3 		$24K Buy
+115
New +$28.6K ﹤0.01% 6969

Other funds holding INAB

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

UBS Group's INAB Position: Q1 2026 in Review

UBS Group reduced its IN8bio (INAB) stake by 38% in Q1 2026, selling an estimated $574 and leaving 480 shares worth $710. The position accounts for ﹤0.01% of the portfolio, ranked #9776.

UBS Group first reported a position in INAB in Q3 2021 and has held it in 16 quarters since. The position peaked at $24K in Q3 2021. 19 funds tracked by Wall St. Rank hold INAB as of Q1 2026.

  • UBS Group held 480 shares of IN8bio worth $710 as of Q1 2026.
  • UBS Group sold 297 IN8bio shares in Q1 2026, an estimated $574.
  • IN8bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9776 holding.
  • UBS Group first reported a position in IN8bio in Q3 2021 and has held it in 16 quarters since.
  • UBS Group's IN8bio position peaked at $24K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held IN8bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.